<DOC>
	<DOCNO>NCT01787149</DOCNO>
	<brief_summary>A Prospective , Randomized , Double-Blind , Placebo-Controlled , Parallel-Group , Multicentre , Phase III Study Evaluate Efficacy Safety ENIA11 Combination DMARDs versus DMARDs Alone Patients Rheumatoid Arthritis</brief_summary>
	<brief_title>A Prospective , Randomized , Double-Blind , Placebo-Controlled , Parallel-Group , Multicentre , Phase III Study Evaluate Efficacy Safety ENIA11 Combination With DMARDs Versus DMARDs Alone Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>The objective study evaluate efficacy safety ENIA11 combination DMARDs versus DMARDs alone patient rheumatoid arthritis . This multi-center , double-blind , randomize , parallel-group , placebo-controlled study evaluate efficacy safety ENIA11 combination DMARDs versus DMARDs alone patient rheumatoid arthritis . The study period patient 28 week , patient undergo screen 14 day , follow treatment 24 week follow-up period 2 week . Each patient require make total 9 visit .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>1 . Male female patient age ≥ 20 year old ; 2 . Patient meet ACR criterion rheumatoid arthritis 6 month duration ; 3 . Patient active disease time screen define six swollen joint six tender joint ; 4 . Presence least one follow criterion : Erythrocyte Sedimentation Rate ( ESR ) ≥ 28 mm/h , CReactive Protein ( CRP ) ≥ 10 mg/L , 5 . RA functional class I , II , III ; 6 . Patients receive stable dos permit DMARDs ( methotrexate , hydroxychloroquine , sulfasalazine , azathioprine , leflunomide ) least 8 week prior enrollment . 7 . Patient willing able comply study procedure sign inform consent . 1 . Active autoimmune disease ( RA ) require immunosuppressive therapy ; 2 . In opinion investigator , patient show persistent sign immunosuppression ; 3 . Known hypersensitivity etanercept ENIA11 component ; 4 . Previous unsuccessful treatment etanercept , antiTNF monoclonal antibody soluble TNF receptor ( e.g. , infliximab ) ; 5 . Suspected diagnosed pulmonary tuberculosis , chronic current infectious disease discretion investigator ; 6 . Patients history evidence medical condition would expose undue risk significant adverse event course trial , include limited hepatic , renal , respiratory , cardiovascular , endocrine , immune , neurological , hematological , gastrointestinal psychiatric disease determine clinical judgment investigator ; 7 . Patients follow laboratory abnormality : ALT/AST &gt; 3 time ULN , creatinine &gt; 2 mg/dl , WBC &lt; 3,000/mm3 , Hgb &lt; 8.5 g/dL , platelet count &lt; 100,000/mm3 ; 8 . Patients receive live attenuated vaccination program within 3 month BCG vaccine within 12 month prior enrollment ; 9 . Female patient childbearing potential : lactating ; positive urine pregnancy test Visit 1 ; refuse adopt reliable method contraception study ; 10 . Diagnosis primary fibromyalgia joint inflammatory disease include limited gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease ; 11 . Known suspected positive serology human immunodeficiency , hepatitis B C virus ; 12 . Patient receive investigational agent within 28 day 5 halflives , whichever longer , prior first dose investigational product ; 13 . Patient history substance abuse , drug addiction alcoholism ; 14 . Patient participate prior phase I/II clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ENIA11</keyword>
	<keyword>DMARDs</keyword>
	<keyword>RA</keyword>
	<keyword>TNF</keyword>
</DOC>